Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | FABP3 | P05413 | 4/20 | 0.32 |
| ▸ | FABP4 | P15090 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.30 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
| ▸ | PTGIR | P43119 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7529067 | 0.92 | ADORA1 (0.39) | ADORA1HPGDKDM4EALDH1A1PTGIR | |
| SCHEMBL7523923 | 0.86 | ADORA1 (0.38) | ADORA1HPGDKDM4EALDH1A1PTGIR | |
| SCHEMBL7521965 | 0.84 | PTGIR (0.40) | HPGDKDM4EALDH1A1PTGIRKMT2A | |
| SCHEMBL7520497 | 0.82 | ADORA1 (0.40) | ADORA1LMNAFABP3FABP4HPGD | |
| SCHEMBL7524911 | 0.79 | PTGIR (0.39) | HPGDKDM4EALDH1A1PTGIRKMT2A | |
| SCHEMBL7528838 | 0.78 | ADORA1 (0.39) | ADORA1FABP3FABP4HPGDALDH1A1 | |
| SCHEMBL8320734 | 0.77 | ADORA1 (0.44) | ADORA1LMNAFABP3FABP4HPGD | |
| SCHEMBL7528912 | 0.77 | KDM4E (0.37) | LMNAHPGDKDM4EALDH1A1MAPT | |
| SCHEMBL7529216 | 0.75 | MAPT (0.42) | ADORA1LMNAHPGDKDM4EALDH1A1 | |
| SCHEMBL7526545 | 0.75 | ADORA1 (0.38) | ADORA1FABP3FABP4HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | ADORA1 210/4885LMNA 2418/4885FABP3 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.